Experiences of participation in activities among girls with juvenile idiopathic arthritis: A qualitative study

Since the discovery of insulin 100 years ago, insulin preparations have improved significantly. Starting from purified animal insulins, evolving to human insulins produced by genetically modified organisms, and ultimately to insulin analogues, all to mimic physiological insulin action profiles seen in individuals without diabetes. Achieving strict glucose control without hypoglycemia and preventing chronic complications of diabetes while preserving the quality of life remains a challenging goal, but the advent of newer ultra‐rapid‐acting insulin analogues may enable intensive insulin therapy without being too disruptive to daily life. Ultra‐rapid‐acting insulin analogues can be administered shortly before meals and give better coverage of mealtime‐induced glucose excursions than conventional insulin preparations. They also increase convenience with timing of bolus dosing. In this review, the study focuses on the progress made in rapid‐acting insulins. The study summarizes pharmacokinetic and dynamic data and clinical trial data supporting the use of these new formulations as part of a basal‐bolus regimen and continuous subcutaneous insulin infusion and provides a clinical perspective to help guide health care professionals when and for whom to use ultra‐fast‐acting insulins.